132 related articles for article (PubMed ID: 38641445)
1. Optimizing the indication of initial radioiodine oncolytic treatment for metastatic differentiated thyroid cancer by diagnostic
He Z; Sa R; Zhang K; Wang J; Qiu X; Chen L
Clin Radiol; 2024 Jul; 79(7):e949-e956. PubMed ID: 38641445
[TBL] [Abstract][Full Text] [Related]
2. Management of differentiated thyroid cancer with rising thyroglobulin and negative diagnostic radioiodine whole body scan.
Chao M
Clin Oncol (R Coll Radiol); 2010 Aug; 22(6):438-47. PubMed ID: 20561773
[TBL] [Abstract][Full Text] [Related]
3. Preablation 131-I scans with SPECT/CT contribute to thyroid cancer risk stratification and 131-I therapy planning.
Avram AM; Esfandiari NH; Wong KK
J Clin Endocrinol Metab; 2015 May; 100(5):1895-902. PubMed ID: 25734251
[TBL] [Abstract][Full Text] [Related]
4. RADIOISOTOPE DIAGNOSTIC ALGORITHM FOR THE RELAPSE AND METASTASES DETECTION IN THE IODINE-NEGATIVE DIFFERENTIATED THYROID CANCER.
Solodyannikova OI; Kmetyuk YV; Danilenko VV; Sukach GG
Probl Radiac Med Radiobiol; 2020 Dec; 25():579-591. PubMed ID: 33361863
[TBL] [Abstract][Full Text] [Related]
5. Clinical usefulness of 99mTc-MIBI scintigraphy in the postsurgical evaluation of patients with differentiated thyroid cancer.
Campennì A; Violi MA; Ruggeri RM; Sindoni A; Moleti M; Vermiglio F; Baldari S
Nucl Med Commun; 2010 Apr; 31(4):274-9. PubMed ID: 20087239
[TBL] [Abstract][Full Text] [Related]
6. The Value of Pre-Ablative I-131 Scan for Clinical Management in Patients With Differentiated Thyroid Carcinoma.
van der Boom T; Zandee WT; Dekkers CCJ; van der Horst-Schrivers ANA; Jansen L; Kruijff S; Brouwers AH; Links TP
Front Endocrinol (Lausanne); 2021; 12():655676. PubMed ID: 34122334
[TBL] [Abstract][Full Text] [Related]
7. Ten Year Experience of Radioiodine Dosimetry: is it Useful in the Management of Metastatic Differentiated Thyroid Cancer?
Sun F; Gerrard GE; Roberts JK; Telford T; Namini S; Waller M; Flux G; Gill VM
Clin Oncol (R Coll Radiol); 2017 May; 29(5):310-315. PubMed ID: 28132755
[TBL] [Abstract][Full Text] [Related]
8. Differentiated Thyroid Cancer Outcomes After Surgery and Activity-Adjusted 131I Theragnostics.
Avram AM; Rosculet N; Esfandiari NH; Gauger PG; Miller BS; Cohen M; Hughes DT
Clin Nucl Med; 2019 Jan; 44(1):11-20. PubMed ID: 30371575
[TBL] [Abstract][Full Text] [Related]
9. Timing of post 131I ablation diagnostic whole body scan in differentiated thyroid cancer patients. Less than four months post ablation may be too early.
Winter M; Winter J; Heinzel A; Behrendt FF; Krohn T; Mottaghy FM; Verburg FA
Nuklearmedizin; 2015; 54(4):151-7. PubMed ID: 26028188
[TBL] [Abstract][Full Text] [Related]
10. Usefulness of iodine-123 whole-body scan in planning iodine-131 treatment of the differentiated thyroid carcinoma in children and adolescence.
Villani MF; Grossi A; Cassano B; Pizzoferro M; Ubertini G; Longo M; Garganese MC
Nucl Med Commun; 2018 Dec; 39(12):1121-1128. PubMed ID: 30260898
[TBL] [Abstract][Full Text] [Related]
11. A Clinical Trial of Optimal Time Interval Between Ablation and Diagnostic Activity When a Pretherapy RAI Scanning Is Performed on Patients With Differentiated Thyroid Carcinoma.
Yin Y; Mao Q; Chen S; Li N; Li X; Li Y
Medicine (Baltimore); 2015 Aug; 94(31):e1308. PubMed ID: 26252311
[TBL] [Abstract][Full Text] [Related]
12. Rate of elimination of radioiodine-avid lymph node metastases of differentiated thyroid carcinoma by postsurgical radioiodine ablation. A bicentric study.
Ilhan H; Mustafa M; Bartenstein P; Kuwert T; Schmidt D
Nuklearmedizin; 2016 Dec; 55(6):221-227. PubMed ID: 27588323
[TBL] [Abstract][Full Text] [Related]
13. Do negative 124I pretherapy positron emission tomography scans in patients with elevated serum thyroglobulin levels predict negative 131I posttherapy scans?
Khorjekar GR; Van Nostrand D; Garcia C; O'Neil J; Moreau S; Atkins FB; Mete M; Orquiza MH; Burman K; Wartofsky L
Thyroid; 2014 Sep; 24(9):1394-9. PubMed ID: 24820222
[TBL] [Abstract][Full Text] [Related]
14. TERT Promoter Mutation Predicts Radioiodine-Refractory Character in Distant Metastatic Differentiated Thyroid Cancer.
Yang X; Li J; Li X; Liang Z; Gao W; Liang J; Cheng S; Lin Y
J Nucl Med; 2017 Feb; 58(2):258-265. PubMed ID: 27493271
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes following empiric radioiodine therapy in patients with structurally identifiable metastatic follicular cell-derived thyroid carcinoma with negative diagnostic but positive post-therapy 131I whole-body scans.
Sabra MM; Grewal RK; Tala H; Larson SM; Tuttle RM
Thyroid; 2012 Sep; 22(9):877-83. PubMed ID: 22827641
[TBL] [Abstract][Full Text] [Related]
16. Peptide receptor radionuclide therapy for non-radioiodine-avid differentiated thyroid carcinoma.
Teunissen JJ; Kwekkeboom DJ; Kooij PP; Bakker WH; Krenning EP
J Nucl Med; 2005 Jan; 46 Suppl 1():107S-14S. PubMed ID: 15653659
[TBL] [Abstract][Full Text] [Related]
17. Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial.
Kiyota N; Robinson B; Shah M; Hoff AO; Taylor MH; Li D; Dutcus CE; Lee EK; Kim SB; Tahara M
Thyroid; 2017 Sep; 27(9):1135-1141. PubMed ID: 28665259
[TBL] [Abstract][Full Text] [Related]
18. Examining recombinant human TSH primed ¹³¹I therapy protocol in patients with metastatic differentiated thyroid carcinoma: comparison with the traditional thyroid hormone withdrawal protocol.
Rani D; Kaisar S; Awasare S; Kamaldeep ; Abhyankar A; Basu S
Eur J Nucl Med Mol Imaging; 2014 Sep; 41(9):1767-80. PubMed ID: 24687139
[TBL] [Abstract][Full Text] [Related]
19. Long-term course and predictive factors of elevated serum thyroglobulin and negative diagnostic radioiodine whole body scan in differentiated thyroid cancer.
Alzahrani AS; Mohamed G; Al Shammary A; Aldasouqi S; Abdal Salam S; Shoukri M
J Endocrinol Invest; 2005 Jun; 28(6):540-6. PubMed ID: 16117196
[TBL] [Abstract][Full Text] [Related]
20. The prostate-specific membrane antigen (PSMA)-targeted radiotracer
Santhanam P; Russell J; Rooper LM; Ladenson PW; Pomper MG; Rowe SP
Med Oncol; 2020 Oct; 37(11):98. PubMed ID: 33034761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
